Overview

Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Status:
Completed

Trial end date:
2017-08-03

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if the combination of azacitidine and vorinostat can help to control AML or MDS better than azacitidine alone. The safety of this drug combination will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

Celgene Corporation
Merck Sharp & Dohme Corp.

Treatments:

Azacitidine
Vorinostat